NASDAQ:JUNO - Juno Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$86.96 0.00 (0.00 %)
(As of 03/6/2018)
Previous Close$86.96
Today's Range$86.96 - $86.96
52-Week Range$19.62 - $87.01
Volume2 shs
Average Volume5.48 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO News and Ratings via Email

Sign-up to receive the latest news and ratings for JUNO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:JUNO
CUSIPN/A
Phone+1-206-5821600

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableOptionable

Juno Therapeutics (NASDAQ:JUNO) Frequently Asked Questions

What is Juno Therapeutics' stock symbol?

Juno Therapeutics trades on the NASDAQ under the ticker symbol "JUNO."

How were Juno Therapeutics' earnings last quarter?

Juno Therapeutics Inc (NASDAQ:JUNO) released its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.80) by $0.07. The biopharmaceutical company earned $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. The business's revenue was up 115.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.57) EPS. View Juno Therapeutics' Earnings History.

Has Juno Therapeutics been receiving favorable news coverage?

Media coverage about JUNO stock has been trending positive recently, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Juno Therapeutics earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term.

What other stocks do shareholders of Juno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Juno Therapeutics investors own include Celgene (CELG), Kite Pharma (KITE), bluebird bio (BLUE), Opko Health (OPK), Gilead Sciences (GILD), Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), TherapeuticsMD (TXMD) and Medivation (MDVN).

Who are Juno Therapeutics' key executives?

Juno Therapeutics' management team includes the folowing people:
  • Howard H. Pien, Independent Chairman of the Board (Age 59)
  • Hans Edgar Bishop, President, Chief Executive Officer, Director (Age 53)
  • Sunil Agarwal M.D., President of Research & Development (Age 47)
  • Steven D. Harr M.D., Chief Financial Officer, Head of Corporate Development (Age 46)
  • Hyam I. Levitsky M.D, Executive vice president - Research, chief scientific officer (Age 54)
  • Robert W. Azelby, Executive Vice President, Chief Commercial Officer (Age 49)
  • Ann Lee Ph.D., Executive Vice President - Technical Operations
  • Patrick Y. Yang, Executive Vice President (Age 69)
  • Cynthia Elkins, Chief Information Officer
  • Bernard J. Cassidy, General Counsel, Secretary (Age 62)

When did Juno Therapeutics IPO?

(JUNO) raised $153 million in an IPO on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Leerink Partners was co-manager.

How do I buy shares of Juno Therapeutics?

Shares of JUNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Juno Therapeutics' stock price today?

One share of JUNO stock can currently be purchased for approximately $86.96.

What is Juno Therapeutics' official website?

The official website for Juno Therapeutics is http://www.junotherapeutics.com/.

How can I contact Juno Therapeutics?

Juno Therapeutics' mailing address is 400 Dexter Ave N Ste 1200, SEATTLE, WA 98109-4703, United States. The biopharmaceutical company can be reached via phone at +1-206-5821600.


MarketBeat Community Rating for Juno Therapeutics (NASDAQ JUNO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  437 (Vote Outperform)
Underperform Votes:  354 (Vote Underperform)
Total Votes:  791
MarketBeat's community ratings are surveys of what our community members think about Juno Therapeutics and other stocks. Vote "Outperform" if you believe JUNO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JUNO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/25/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel